






tion  therapy  has  been  successfully 
tried before, for example, using DNA-
damaging  agents.  But  the  elegant 
approach of  targeting the resistance 
pathway (upregulation of Mcl-1) using 
the  new  targeted  therapy  Sorafenib 
is  an  appealing  advance  and  opens 
avenues  for  combining  TRAIL  with 
small molecules or peptides that act 
directly on apoptotic sensitizers and 
effectors  (such  as  stabilized  BH3-
peptides targeting Mcl-1 and/or Bak) 
or other drugs that destabilize Mcl-1. 
However,  a  word  of  caution—sensi-
tizing  TRAIL-resistant  cancer  cells 
may also sensitize normal cells to this 
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EGFR kinase inhibitors constitute an important class of lung cancer treatments. While they 
produce dramatic responses in a subset of patients—primarily those with activating EGFR 
mutations—remissions are typically limited to several months due to acquired drug resistance, 
frequently associated with the secondary T790M mutation in EGFR. In this issue of Cancer Cell, Li 
et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung 
cancer model driven by an EGFR mutant harboring T790M and an activating mutation. However, 
combining HKI-272 with rapamycin promoted rapid tumor regression, suggesting a therapeutic 
strategy to overcome drug resistance.Lung  cancer  remains  the  leading 
cause  of  cancer  deaths  worldwide. 
While  the  disease  is  largely  refrac-
tory  to  conventional  chemotherapy, 
the  recent  emergence  of  selective 
tyrosine  kinase  inhibitors  (TKIs)  that 
elicit  dramatic  clinical  responses  in 
a  subset  of  treated  patients  repre-
sents  a  highly  promising  therapeu-
tic  development.  Specifically,  about 




and  erlotinib  (Tarceva),  small-mol-





ing  EGFR  kinase  domain  mutations ier Inc.in tumors and have been linked to an 
overall survival benefit (Sequist et al., 
2007).
However,  the  excitement  around 








Previewstor  imatinib  in  chronic myelogenous 
leukemia  (CML),  it  is  now  clear  that 
about half of all NSCLC cases in which 
clinical  response  has  been  followed 
by  disease  progression  are  associ-
ated  with  the  acquisition  of  a  sec-
ondary  mutation,  T790M,  within  the 
EGFR kinase domain, which prevents 
drug  binding  while  preserving  cata-
lytic activity  (Kobayashi et al., 2005; 
Pao et al., 2005). Interestingly, EGFR 
T790M  alleles  have  been  detected 
at  lower  frequency  in  untreated 
NSCLCs,  suggesting  that  they  may 
confer  oncogenic  activity  to  EGFR 
in  addition  to  their  role  in  acquired 
drug  resistance  (Soh  et  al.,  2007). 
Thus, there has been great interest in 
developing  “next  generation”  EGFR 
inhibitors  that  can  potentially  over-
come the TKI-resistant T790M allele. 
Such efforts have been further moti-
vated by  the  recent  clinical  success 
of dasatanib, an ABL kinase inhibitor 
that can induce remissions in a sub-
set  of  CML  patients  with  acquired 
resistance to imatinib by overcoming 
some  of  the  secondary  resistance 





that  can  potentially  provide  a  solu-
tion  to  the  T790M  TKI  resistance 
problem (Kwak et al., 2005). Gefitinib 
and  erlotinib  bind  EGFR  reversibly, 
whereas several other investigational 
drugs  can  bind  covalently  to  the 
EGFR  catalytic  pocket  via  a  cyste-
ine residue within the kinase domain. 
One of these drugs, HKI-272, an irre-
versible  dual  inhibitor  of  both  EGFR 
and  HER2,  has  been  demonstrated 
to  suppress  EGFR  signaling  in  the 
context  of  an  EGFR  double-muta-
tion  mutant  that  harbors  both  an 
activating  “primary”  mutation  and 
the T790M substitution  (Kwak et al., 
2005).  Moreover,  HKI-272  can  pro-
mote cell killing more effectively than 
gefitinib/erlotinib  in  cultured  NSCLC 
lines  harboring  EGFR  double-muta-
tion  mutants.  However,  signaling  by 
the EGFR T790M mutant is not com-
pletely  suppressed  by HKI-272,  and 
it  remains  to  be  demonstrated  that 
these  irreversible  inhibitors can pro-vide clinical benefit in NSCLC patients 
that  have  progressed  following  an 
initial  response  to  gefitinib  or  erlo-
tinib. Indeed, early clinical studies of 
HKI-272 have thus far failed to dem-
onstrate  objective  responses  in  this 
setting  (Wong  et  al.,  2006).  Hence, 
further  preclinical  development  may 
be  required before  these  irreversible 
inhibitors  can  be  used  optimally  in 
lung cancer patients.
Mouse  modeling  of  EGFR-driven 
NSCLC  provides  a  potentially  pow-
erful  system  in  which  to  examine 




EGFR  mutants  have  recently  been 
reported,  and  these  mice  develop 
lung  adenocarcinomas  that  exhibit 
histologic  features  characteristic 
of  human  NSCLCs,  and  which  rap-
idly  regress  following  treatment with 
erlotinib  or  HKI-272.  In  this  issue  of 
Cancer Cell, Li and colleagues (Li et 
al.,  2007)  have  utilized  this  system 
to  explore  the  utility  of  HKI-272  in 
the context of  lung cancer driven by 
transgenic  expression  of  an  EGFR 
double-mutation  mutant  that  har-




in  which  the  EGFR  TL  allele  could 
be  expressed  inducibly  (via  doxycy-
cline  administration)  and  specifically 
in  type  II  alveolar  epithelial  cells. As 
expected,  doxycycline-treated  mice 
developed  bronchioalveolar  carci-
noma  that  could  be  readily  visual-
ized by MRI.  Interestingly,  two types 




weeks  of  doxycycline  withdrawal, 
indicating  a  requirement  for  mutant 
EGFR  in  maintaining  the  malignant 
phenotype.
Treatment  of  tumor-bearing  mice 
with erlotinib failed to produce tumor 
regression,  as  would  be  expected 
in  the context of a T790M mutation. 
Among  HKI-272-treated  mice,  there 
was  some  reduction  in  peripheral 
adenocarcinomas  and  partial  tumor Cancerregression,  whereas  no  significant 
effect was seen in bronchial tumors. 






However,  these  unexpected  findings 
warrant  further  investigation.  Over-
all,  the  effect  of  HKI-272  treatment 




regarding  the  therapeutic  value  of 
HKI-272 as a single agent.
Li  and  colleagues  then  demon-
strated that a combination of HKI-272 
and  the  mTOR  inhibitor  rapamycin 
caused significant regression of both 





downstream  of  EGFR  (Adjei,  2006). 
Indeed, several previous reports indi-
cated  a  synergistic  inhibition  of  cul-
tured  lung  cancer  and  glioma  cells 
using EGFR TKIs together with mTOR 
inhibitors (Adjei, 2006; Goudar et al., 
2005).  The  ability  of  the  HKI-272/
rapamycin  combination  to  promote 
more effective suppression of EGFR 
signaling  to  S6  and  AKT  kinases 
was  demonstrated  both  in  cultured 
NSCLC  cell  lines  harboring  double 
mutant EGFR alleles as well as in lung 
tumors in TL mice. The investigators 
suggest  that  HKI-272  may  not  suf-
ficiently  overcome  the  biochemical 
drug resistance conferred by T790M 
and  that  further  suppression  of  an 
essential  AKT-mTOR  signal  down-
stream of EGFR is required to achieve 
a  therapeutic  response.  Although 
the unique effect of combined  treat-
ment  on  both  bronchial  and  alveo-
lar  tumors  is  evidence of  synergy at 
the biologic  level,  the claim  that  this 
drug combination  leads  to  synergis-
tic inhibition of downstream signaling 
is not compelling and would need to 
be  substantiated  by  further  quanti-
tative analysis.  In  fact,  it  is not clear 
that  a  synergistic  effect  of  the  drug 
combination  would  necessarily  be  Cell 12, July 2007 ©2007 Elsevier Inc.  7
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Previewsexpected.  The  fact  that  doxycycline 
withdrawal  is  sufficient  to  promote 
tumor  regression  in  this model  sug-
gests  that  complete  suppression 





bining  drugs  that  target  EGFR  and 
mTOR. Importantly, as the  investiga-
tors suggest, a more effective EGFR 





tial  shortcomings  of  HKI-272  (and 
possibly  other  irreversible  EGFR 
inhibitors)  as  effective  lung  cancer 
drugs,  and  they  reveal  a  potential 
therapeutic role for an HKI-272/rapa-
mycin  combination.  The  study  also 
demonstrates  the  potential  comple-
mentarity  of  mouse  and  cell  culture 
models for the testing of such agents 
preclinically.  Li  and  colleagues   Cancer Cell 12, July 2007 ©2007 Elsevobtained essentially  identical  results 
using  cultured  human  NSCLC  lines 
and  transgenic mice,  revealing  both 
the  limited  efficacy  of  HKI-272  as  a 
single  agent  and  the  potential  value 
of  the  combination  with  rapamycin. 
Unexpectedly,  the  mouse  model 
studies further revealed that HKI-272 
was  efficacious  against  alveolar  but 
not  bronchial  tumors,  and  HKI-272 
resistance  in  bronchial  tumors  was 
overcome  by  the  addition  of  rapa-
mycin.  Of  course,  the  ultimate  test 
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